Across TCGA pan-cancer cohorts, SNORD116-26 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SNORD116-26 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher SNORD116-26 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNORD116-26 expression acts as an unfavorable survival marker.
COAD are the cancer types where SNORD116-26 Mutation most reproducibly stratifies survival.